- Launch of brain imaging analysis tools like ‘안전한 바카라 사이트 AQUA AD’ to monitor side effects of dementia treatments
- Collaborating with major global pharmaceutical and neurology KOLs… Aiming for global development partnerships for key products
[by Kang, In Hyo] Neurophet, an artificial intelligence (AI) company specializing in the diagnosis and treatment of brain diseases, announced on July 24 its participation in the Alzheimer’s Association International Conference (AAIC 2025), where it will present its flagship brain imaging analysis AI solution.
Jake Junkil Been, co-CEO of 안전한 바카라 사이트, will deliver a presentation at the conference titled, ‘안전한 바카라 사이트 in the era of Alzheimer’s disease paradigm shift: The journey to IPO and beyond.’
At the conference, 안전한 바카라 사이트 will introduce ‘안전한 바카라 사이트 AQUA AD,’ a software platform designed to monitor prescriptions, treatment efficacy, and adverse effects of dementia treatments. 안전한 바카라 사이트 AQUA AD provides advanced quantitative analysis of magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, enabling precise brain imaging assessments throughout the entire course of anti-amyloid antibody drug administration.
With the pharmaceutical and biotechnology industries accelerating the development of Alzheimer's disease treatments, the need for solutions capable of accurately managing prescriptions, treatment outcomes, and adverse effects has become increasingly prominent. In particular, as side effect monitoring is critical for Alzheimer's treatments such as 'LEQEMBI (lecanemab)' and 'Kisunla (donanemab),' global demand and expectations are rising for 안전한 바카라 사이트 AQUA AD, which offers the capability to analyze brain imaging biomarkers related to such adverse effects.
At the conference, 안전한 바카라 사이트 will showcase 안전한 바카라 사이트 AQUA AD alongside its other flagship solutions, including '안전한 바카라 사이트 AQUA,' a brain neurodegeneration image analysis software, and '안전한 바카라 사이트 SCALE PET,' a quantitative PET image analysis software.
Through its participation in AAIC 2025, 안전한 바카라 사이트 aims to establish partnerships with major global pharmaceutical companies and potential clients for business development cooperation. The company also plans to engage with key opinion leaders in neurology, emphasize the distinctive competitiveness of its products, and strengthen its collaborative network.
“안전한 바카라 사이트 AQUA AD is emerging as a key collaboration partner for numerous Korean and international companies in the field of brain imaging biomarkers,” stated Jake Junkil Been, co-CEO of 안전한 바카라 사이트. “Through our participation in AAIC 2025, we intend to further accelerate global development cooperation for our core products, including 안전한 바카라 사이트 AQUA AD.”
On the other hand, AAIC 2025 is an international conference bringing together dementia researchers and neurology clinicians and will take place in Toronto, Canada. The event is scheduled to run for five days, from July 27 to 31 (local time).